Q uadrivalent human papillomavirus (HPV) vaccine greatly reduces the incidence of several types of HPV infections in adolescents who have not been previously infected by these genotypes. The drug represents a significant advance since it reduces the incidence of high-grade dysplasia. Adverse events also appear to be minor.
The HPV vaccine, approved in 2006, is indicated in girls and women 9 to 26 years of age for the prevention of the following diseases caused by HPV types 6, 11, 16, and 18: cervical cancer, genital warts (condyloma acuminata), cervical adenocarcinoma in situ (AIS), cervical intraepithelial neoplasia (CIN) grade 2 and 3, vulvar intraepithelial neoplasia (VIN) grade 2 and 3, and vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3.
At the time of approval, the most common adverse effects associated with the HPV vaccine were fever, injection-site related pain, swelling, erythema, and pruritus. Injection-site reactions were judged mild to moderate in the majority of patients, although pain was judged severe in 4.5% of recipients. New medical conditions indicative of a systemic-immune disorder developed within up to 4 years after vaccination in nine vaccine recipients (0.076%; one juvenile arthritis, two rheumatoid arthritis, five unspecified arthritis, and one reactive arthritis) and three placebo recipients (0.031%; including one systemic lupus erythematosus and two unspecified arthritis). 1 The Vaccine Adverse Event Reporting System (VAERS) was created by the Food and Drug Administration and Centers for Disease Control and Prevention to monitor adverse event reports that are potentially associated with the administration of vaccines. It should be remembered that a submission of a VAERS report does not establish causality, but aggregate data may be useful in identifying and monitoring the safety profile of vaccines. Pharmacists, regardless of practice setting, should utilize the VAERS system to report any untoward events that may be related to any vaccine.
It should be noted that one of the recognized limitations of a voluntary reporting program in under-reporting and incomplete reports. Via the Freedom of Information Act, a total of 2,526 adverse event reports possibly associated with the HPV vaccine were submitted to VAERS. While the majority of these were not serious, more data were needed on several reports. For example, a 12year-old with a medical history of aortic and mitral valve insufficiency died following a first dose of Gardasil, a second dose of Varivax, and a second dose of Vaqta; this patient presented to the emergency department with ventricular tachycardia. In another report, a 19year-old expired 14 days after the first dose of Gardasil from "sudden cardiac death and pulmonary embolism." Additionally, a 22year-old developed severe urticaria and angioedema 24 to 48 hours following the first HPV vaccine dose, requiring high-dose steroids for 10 days to control symptoms. It is not possible to determine definitive causality based on these reports alone-as not enough information was presented nor known. The impetus of requesting further information via the Freedom of Information Act request was precipitated by anonymous public information available in the media. These reports, as anticipated, were scurrilous.
Again, all health professionals are encouraged to submit vaccine adverse events to VAERS; reporting these vaccine-related problems serves an important public health benefit when causality can be determined in evaluation of aggregate data. For those serious, vaccinerelated, adverse events that have been properly validated with an established cause-and-effect relationship, health professions should be notified as soon as possible.
